Diagnovus becomes first licensee to MPEG LA's Librassay licensing programme

MPEG LA today announced that Diagnovus has entered into a licence for certain patent rights through Librassay, a new one-stop patent licensing programme in the field of molecular diagnostics offered by patent licensing leader MPEG LA.

"We are pleased to welcome Diagnovus as a licensee to the Librassay programme," said Larry Horn, President and CEO of MPEG LA. "MPEG LA, through Librassay, provides a solution to the market's growing need for one-stop, non-exclusive access to patent rights for diagnostic tests that lead to personalised medical solutions. Just as MPEG LA's origination of patent pools provided a market-based solution for accessing consumer electronics, video and information technologies, MPEG LA's Librassay delivers a similar solution to the healthcare market with the potential for profound cost savings and quality of life benefits."

"Librassay is the answer to a growing market need for licences under patents in support of emerging gene panel tests," stated James Stover, Ph.D., Vice-President of Business Development at Diagnovus. "When the patents are held by many different entities, securing licences with each of them can be a challenge - especially for a small, fast-moving company like Diagnovus. We welcome the convenience of Librassay's efficient, cost-effective, one-stop licensing platform. By enabling us to access patent rights in a single transaction, Librassay allowed Diagnovus to quickly secure a licence and add to our ENGAUGE product line, saving valuable resources for what we do best - delivering personalised information and services to physicians treating patients suffering from under-served, aggressive and lesser-known diseases."

"We welcome diagnostic developers and service providers, large and small, to visit the Librassay Web site and contact us directly to lock in access to diagnostic patent rights held by a growing number of world-class research institutions," added Kristin Neuman, Librassay Executive Director.

Launched in September 2012 (http://www.mpegla.com/Lists/MPEG%20LA%20News%20List/Attachments/83/n-12-09-27.pdf), Librassay makes diagnostic patent rights from the world's leading research institutions available to everyone through a single licence. It also offers patent holders the opportunity for wider adoption of their technologies, reasonable compensation for their research investments, and the incentive to invest more. The programme currently includes some 400 patents owned by Johns Hopkins University; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH); Partners HealthCare; The Board of Trustees of the Leland Stanford Junior University; The Trustees of the University of Pennsylvania; University of California, San Francisco; and Wisconsin Alumni Research Foundation (WARF).

To access the online Librassay store, or request a copy of the Librassay Patent Portfolio License, please go to www.librassay.com.